Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Stop Linking Payment For Aranesp, Procrit But Vows To Revisit Issue

Executive Summary

CMS remains open to aligning the payment rate for Amgen's Aranesp with Johnson & Johnson's Procrit in future years, although for now the agency is acting on its proposal to retire the "equitable adjustment" method for reimbursing the drugs
Advertisement

Related Content

EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp
Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill
Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill
EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp
Medicare Aranesp Reimbursement Drops “Equitable Adjustment” To Procrit
Medicare Aranesp Reimbursement Drops “Equitable Adjustment” To Procrit

Topics

Advertisement
UsernamePublicRestriction

Register

PS046512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel